1. Home
  2. Programs
  3. CME/CE
  4. AF and VTE: Global Considerations in the Evolving Space of Real-World Data

MinuteCE®

AF and VTE: Global Considerations in the Evolving Space of Real-World Data

Patient Case Study: Obesity

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take 1 Minute Challenge
0.00 of 1.00 program credits
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
  • Overview

    The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you’re up to date and providing the care your patients deserve. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Renato D. Lopes, MD, MHS, PhD
    Professor of Medicine, Division of Cardiology
    Duke University Medical Center
    Duke Clinical Research Institute
    Durham, NC

    Dr. Lopes has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Novo Nordisk, Pfizer
    Contracted Research: Amgen, Bristol-Myers Squibb, Glaxo Smith Kline, Medtronic, Pfizer, Sanofi

    Faculty: 
    Valeria Caso, MD, PhD
    Stroke Unit
    Santa Maria della Misericordia Hospital
    Perugia, Italy

    Dr. Caso has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, BMS, Daiichi Sankyo, Ever Pharma, Pfizer

    Alexander T. Cohen, MD, MBBS
    Consultant Vascular Physician
    Guy’s and St Thomas' NHS Foundation Trust
    King's College London
    London, UK

    Dr. Cohen has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Bayer, BMS, Pfizer
    Contracted Research: AstraZeneca, Medtronics

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has no relevant relationships to disclose.
    • Anita Galdieri, PharmD, has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
    • Katie Sheridan, PhD, has no relevant relationships to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the challenges in using real-world evidence when making clinical decisions in everyday practice for the management of atrial fibrillation (AF) or venous thromboembolism (VTE)​
    • Optimize the selection process for oral anticoagulation in patients with AF or VTE, balancing bleeding risk with thrombotic risk reduction
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and generalists as well as all other physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with AF and VTE. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-0000-25-016-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until February 14, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 60 minutes of effective education time.

  • Provider(s)/Educational Partner(s)

     

     


    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Program Episodes
0 of 0 completed
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free